Kriya Therapeutics has raised $100m in Series B funding round to advance its platform for designing, developing and producing next-generation gene therapies.

Patient Square Capital led the funding round with new investors Woodline Partners, CAM Capital, Hongkou and Alumni Ventures, among others, taking part.

The funding round also saw participation from current institutional investors, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.

The funds will be utilised to advance Kriya’s core technology platforms, extend its treatment pipeline and develop its existing programmes in metabolic disease, ophthalmology and oncology.

Kriya Therapeutics co-founder and CEO Shankar Ramaswamy said: “Kriya was formed with the mission of revolutionising how gene therapies are designed, developed and produced by fully integrating advanced manufacturing technologies, computational tools and development capabilities within a single company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“With the support of our new and existing investors, we believe that Kriya is well-positioned to deliver transformative improvements in cost, scale and efficiency that will help the gene therapy field achieve its full potential across a range of therapeutic areas.”

As part of the funding, Patient Square Capital managing partner Jim Momtazee will be appointed to the board of directors of Kriya.

By integrating developments in computer science and vector biology, Kriya is developing the System for Intelligent Rational Vector Engineering (SIRVE) platform to enable de novo vector design, sequence alternation and analysis of data.

Kriya is using SIRVE to develop in-house gene therapy programmes and enhance first-generation products in a bid to lower immunogenicity and boost expression and packaging efficiency.

System to Realize Improved Production Efficiency (STRIPE) is another manufacturing platform developed by Kriya. STRIPE merges developments in cell line technology and upstream and downstream process to attain substantial decreases in production costs.

In a separate development, Ribon Therapeutics has raised $65m in a funding round led by Deerfield Management and US Venture Partners.

The funds will be used to clinically progress Ribon’s new precision medicine candidates.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.